Latest news with #StructureTherapeuticsInc
Yahoo
24-06-2025
- Business
- Yahoo
Jefferies Reiterates a Buy Rating on Structure Therapeutics (GPCR) With a $79 PT
Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 13 Small Cap Stocks Analysts Are Bullish On. Jefferies analyst Roger Song maintained a Buy rating on Structure Therapeutics Inc. (NASDAQ:GPCR) on June 5, setting a price target of $79.00. The analyst reasoned that Structure Therapeutics Inc. (NASDAQ:GPCR) is poised to experience a catalyst-rich H2 2025 as its clinical trials are expected to undergo significant developments. Management expects two Phase 2b readouts in Q4, along with the initiation of the amylin first-in-human study by the end of the year. A scientist in a lab coat observing a beaker with colored liquid as it bubbles and hisses. According to Song, these milestones are critical as they can determine the safety and efficacy of the compounds, especially the '1290 compound, with the potential to differentiate from competitors. Structure Therapeutics Inc. (NASDAQ:GPCR) is also exploring strategic partnerships for commercialization and ensuring manufacturing readiness as part of strategic preparations for Phase 3 trials. The analyst considers it well-positioned to capitalize on emerging opportunities and advance its clinical programs, supported by a cash runway extending to 2027. Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage global biopharmaceutical company that develops novel oral therapeutics for the treatment of a range of chronic diseases with unmet medical needs. The company's pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. While we acknowledge the potential of GPCR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
29-05-2025
- Business
- Yahoo
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences
SAN FRANCISCO, May 29, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced that management will participate in multiple upcoming healthcare conferences in June. Jefferies Global Healthcare Conference Format: Fireside chat and 1x1 meetingsDate/time: Thursday, June 5 at 8:10 a.m. ETLocation: New York, NY Goldman Sachs Global Healthcare Conference Format: Fireside chat and 1x1 meetingsDate/time: Wednesday, June 11 at 10:40 a.m. ETLocation: Miami, FL The live and archived webcasts of the fireside chats will be accessible from the company's website at and a replay will be available for 90 days. About Structure Therapeutics Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit Investors:Danielle KeatleyStructure Therapeutics Media:Dan Budwick1ABDan@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25-04-2025
- Business
- Yahoo
Is Structure Therapeutics Inc. (NASDAQ:GPCR) the Most Promising Small-Cap Stock According to Analysts?
We recently published a list of the 11 Most Promising Small-Cap Stocks According to Analysts. In this article, we are going to take a look at where Structure Therapeutics Inc. (NASDAQ:GPCR) stands against other promising small-cap stocks. Robert Teeter of Silvercrest Asset Management recently appeared in an interview to express that he thinks small-cap stocks are currently facing a choppy market, but he also acknowledged that he anticipates a rally later in the year. Based on this sentiment, he advised clients on the importance of diversification within the S&P 500 and pointed to opportunities in international markets. We covered his stance in greater detail in one of our other articles, 10 Best Small-Cap Value Stocks to Buy Now. Here's an excerpt from it: 'He noted that the Trump trade initially boosted small caps due to expectations of economic acceleration and lower interest rates, both of which are favorable for these companies. However, policy uncertainty and weaker-than-expected economic data have delayed their rally. Teeter believes that small caps will come into their own later in the year, but for now, they are facing a choppy market with significant rotation.' However, later on March 26, Villere & Co. Portfolio Manager George Young joined 'Market Domination Overtime' on Yahoo Finance to discuss why investors should be looking at small-cap stocks. George Young stated that small caps currently appear cheap and have been underperforming relative to larger stocks. He highlighted that small-cap stocks have been inexpensive for a while. To support his stance, he pointed out that last year, the S&P 500 rose about 25%, while small-cap stocks increased by only 11%. He explained that this disparity suggests a regression to the mean at some point, which means that the valuation gap between small caps and large caps should eventually narrow. Young also noted a shift in market dynamics during Q1 of this year. While the S&P 500 was down ~2% then, the S&P 500 excluding the MAG7 stocks was actually up ~2%. He described this change as a relatively usual once, since stock market leadership often rotates between sectors and types of stocks. Young particularly favored the small-cap sector when questioned about long-term and steady investments. We sifted through the Finviz stock screener to compile a list of the top small-cap stocks that were trading between $300 million and $2 billion, and that had the highest upside potential (at least 40%). The stocks are ranked in ascending order of their upside potential. We have also added the hedge fund sentiment for each stock, as of Q4 2024, which was sourced from Insider Monkey's database. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here). A scientist in a lab coat observing a beaker with colored liquid as it bubbles and hisses. Market Capitalization as of April 23: $1.34 billion Number of Hedge Fund Holders: 40 Average Upside Potential as of April 23: 239.27% Structure Therapeutics Inc. (NASDAQ:GPCR) develops and delivers oral small-molecule therapeutics to treat various chronic diseases with unmet medical needs in the US. Its lead product candidate is GSBR-1290 (Aleniglipron), which is an oral and biased small-molecule agonist of the GLP-1 receptor. It's in two-phase 2 clinical trials for the treatment of obesity and related conditions. The company's Aleniglipron program is central to its strategy in the obesity market. As of February, enrollment is fully completed in both the ACCESS study (~220 adults) and the ACCESS II study (~80 adults), which totals over 300 patients. These studies are evaluating different dose levels (up to 120 mg in ACCESS and higher doses of 180 mg and 240 mg in ACCESS II) with optimized 4-week titration regimens. Topline 36-week data from both ACCESS and ACCESS II are anticipated by year-end 2025. Positive data from these studies would position aleniglipron as a potentially best-in-class oral GLP-1 small molecule, with the advantage of being combinable with other medicines. With 36-week data expected by the end of 2025, this program is the most advanced in Structure Therapeutics Inc.'s (NASDAQ:GPCR) portfolio and is expected to influence the company's overall growth trajectory. Overall, GPCR ranks 3rd on our list of the most promising small-cap stocks according to analysts. While we acknowledge the growth potential of GPCR, our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than GPCR but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
